Cathelicidin (hCAP-18 / Synthetic Derivatives) vs Thymosin Alpha-1
Human cationic antimicrobial protein-18 (hCAP-18) precursor and its synthetic derivative SAAP-148 — a next-generation 24-amino-acid cathelicidin-based peptide with broad-spectrum bactericidal activity against multidrug-resistant ESKAPE pathogens including MRSA biofilms, superior potency to its parent fragment LL-37, and retained efficacy under physiological salt and plasma conditions
Your immune system's master trainer—a naturally occurring thymus peptide that wakes up tired immune cells, helps your body fight infections, and keeps your defenses sharp as you age.
Written by Michael Carroll — Owner, Director of Research · Reviewed by the Peptide Initiative Research Team · Editorial standards
Quick comparison
Dose range
Cathelicidin (hCAP-18 / Synthetic Derivatives)
0.5–0.5 mg/mL
Thymosin Alpha-1
1.6–1.6 mg
Frequency
Cathelicidin (hCAP-18 / Synthetic Derivatives)
Once daily
Thymosin Alpha-1
Twice weekly
Administration
Cathelicidin (hCAP-18 / Synthetic Derivatives)
Topical application (primary research route)
Thymosin Alpha-1
Subcutaneous injection
Cycle length
Cathelicidin (hCAP-18 / Synthetic Derivatives)
4-6 weeks
Thymosin Alpha-1
8-12 weeks
Onset speed
Cathelicidin (hCAP-18 / Synthetic Derivatives)
Rapid (hours to days)
Thymosin Alpha-1
Moderate (1-2 weeks)
Evidence level
Cathelicidin (hCAP-18 / Synthetic Derivatives)
Moderate human trials (Phase 1-2)
Thymosin Alpha-1
Moderate human trials (Phase 1-2)
Benefit ratings
Antibiotic-Resistant Infections
Biofilm Destruction
Immune System Support
Immune Activation
Infection Fighting
Immune Balance
Compound specifications
Cathelicidin (hCAP-18 / Synthetic Derivatives)
Molecular formula
hCAP-18: ~18 kDa precursor protein (170 AA); SAAP-148: C155H253N49O31 (approximate), MW 3,267.1 Da
Molecular weight
hCAP-18 precursor: ~18,000 Da; SAAP-148: 3,267.1 Da; OP-145: ~2,900 Da
Half-life
Plasma half-life: minutes (proteolytic degradation); local tissue persistence: hours at therapeutic concentrations in wound environment; enhanced stability compared to LL-37 due to N-terminal acetylation and C-terminal amidation
Bioavailability
Topical bioavailability optimized in hypromellose ointment formulations; SAAP-148 retains activity in human plasma unlike LL-37; systemic bioavailability limited by proteolytic degradation
CAS number
Not assigned (SAAP-148 and OP-145 are novel synthetic derivatives)
Thymosin Alpha-1
Molecular formula
C129H215N33O55
Molecular weight
3108.32 g/mol
Half-life
Approximately 2 hours
Bioavailability
High when injected subcutaneously (rapid absorption, peak at ~2 hours)
CAS number
62304-98-7
Dosing compared
Cathelicidin (hCAP-18 / Synthetic Derivatives)
Topical
0.5 mg/mL drops (about 100 microliters per application)
Twice daily · 2 weeks
In a human phase 2a ear study, OP-145 drops at 0.5 mg per mL were applied to the affected ear twice daily for 2 weeks and were safe and well tolerated [4].
Thymosin Alpha-1
Subcutaneous injection
1.6 mg
Twice weekly (3-4 days apart) · 6-12 months
Established clinical dose for thymalfasin (Zadaxin); body-surface-scaled as 900 mcg/m2 [4][6]. Phase III chronic hepatitis B trials used 1.6 mg SC twice weekly for 6-12 months [4].
1.6 mg daily, then 1.6 mg twice weekly
Daily for an initial loading period, then twice weekly · 12+ weeks
The schedule used in a randomized trial in HBV-related acute-on-chronic liver failure: 1.6 mg daily for the first week, then twice weekly to week 12 [3].
Best suited for
Cathelicidin (hCAP-18 / Synthetic Derivatives)
Research into next-generation antimicrobials against multidrug-resistant infections
Cathelicidin (hCAP-18 / Synthetic Derivatives) is particularly well-suited for individuals focused on research into next-generation antimicrobials against multidrug-resistant infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Topical antimicrobial development for wound infections with biofilm involvement
Cathelicidin (hCAP-18 / Synthetic Derivatives) is particularly well-suited for individuals focused on topical antimicrobial development for wound infections with biofilm involvement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Understanding vitamin D-cathelicidin innate immune axis for immune optimization
Cathelicidin (hCAP-18 / Synthetic Derivatives) is particularly well-suited for individuals focused on understanding vitamin d-cathelicidin innate immune axis for immune optimization. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Development of anti-biofilm therapeutics for chronic device-related and wound infections
Cathelicidin (hCAP-18 / Synthetic Derivatives) is particularly well-suited for individuals focused on development of anti-biofilm therapeutics for chronic device-related and wound infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Thymosin Alpha-1
Chronic Hepatitis B or C Support
Thymosin Alpha-1 has its strongest clinical evidence here. Multiple trials show it helps clear viral loads and normalize liver enzymes, especially when combined with antiviral medications. It's approved in over 30 countries specifically for hepatitis treatment.
Cancer Treatment Support
When used alongside chemotherapy, Thymosin Alpha-1 may help maintain immune function that chemo tends to suppress. Research in lung cancer, melanoma, and liver cancer shows improved outcomes when added to standard treatments. It helps your immune system keep fighting even during tough treatments.
Age-Related Immune Decline
As you age, your thymus shrinks and produces less thymosin naturally—a process called immunosenescence. Supplementing with Thymosin Alpha-1 may help compensate, keeping your immune defenses more youthful and responsive. Think of it as replacing what your body makes less of over time.
Severe Infection Recovery
In sepsis and critical infections, Thymosin Alpha-1 has shown promise for reducing mortality by helping restore immune balance. It's particularly interesting because it modulates immunity rather than just boosting it—calming overreaction while enhancing pathogen-fighting ability.
Side effects
Cathelicidin (hCAP-18 / Synthetic Derivatives)
Common
- Local application site irritation
- Local inflammatory response
- Mild wound exudate increase
Uncommon
- Localized urticaria
- Transient pain at injection site
Serious
- Hemolytic activity at supratherapeutic doses
Thymosin Alpha-1
Common
- Injection site reactions
Uncommon
- Mild fatigue
- Flu-like symptoms
- Mild fever
- Lymph node awareness
Serious
- Allergic reaction
Safety & evidence
Cathelicidin (hCAP-18 / Synthetic Derivatives)
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Cathelicidin peptides (natural and synthetic) are not FDA-approved. Human data are limited: in a randomized Phase IIa trial, ear drops of the LL-37-derived peptide OP-145 were safe and well tolerated in chronic middle-ear infection [3][4]. Animal studies demonstrate broad-spectrum antimicrobial activity without systemic toxicity at therapeutic concentrations. However, concern exists regarding immunological tolerance—cathelicidin derivatives can trigger innate immune activation and inflammatory responses at high concentrations. The peptide's mechanism on immune cells is incompletely understood in humans, and effects on chronic immune signaling, tolerance development, or off-target immune activation remain uncharacterized. Bacterial resistance development to cathelicidin-based therapeutics is theoretically possible but not yet documented clinically.
Contraindications
- Known hypersensitivity to cathelicidin-derived peptides or formulation components
- Pregnancy and breastfeeding — insufficient reproductive safety data for synthetic derivatives
- Active autoimmune conditions involving cathelicidin dysregulation (e.g., rosacea, psoriasis) — exogenous cathelicidin peptides may exacerbate inflammation
- Severe systemic immunodeficiency without medical supervision — immune modulation effects may be unpredictable
Thymosin Alpha-1
Evidence level
Moderate human trials (Phase 1-2)
FDA status
Not FDA approved. There is no thymalfasin application in Drugs@FDA. It is used outside the US (as Zadaxin) for chronic hepatitis B and as an immune adjuvant.
Safety overview
Thymosin Alpha-1 has one of the most extensive safety records of any peptide, with decades of clinical use across multiple countries. Studies consistently report minimal side effects—mostly limited to mild injection site reactions. The 2-hour half-life means it doesn't accumulate in your system. It's been used safely in thousands of patients with hepatitis, cancer, and other serious conditions.
Contraindications
- Organ transplant recipients on immunosuppressants
- Active autoimmune disease flares
- Known allergy to thymosin peptides
- Pregnancy or breastfeeding
- Children under 18 without medical supervision
Which is right for you?
Choose Cathelicidin (hCAP-18 / Synthetic Derivatives) if...
- Research into next-generation antimicrobials against multidrug-resistant infections
- Topical antimicrobial development for wound infections with biofilm involvement
- Understanding vitamin D-cathelicidin innate immune axis for immune optimization
- Development of anti-biofilm therapeutics for chronic device-related and wound infections
Choose Thymosin Alpha-1 if...
- Immune system strengthening
- Chronic infection support
- Cancer adjunct therapy
- Healthy aging immune support